表紙
市場調查報告書

特發性肺纖維化:開發中產品分析

Idiopathic Pulmonary Fibrosis - Pipeline Review, H1 2020

出版商 Global Markets Direct 商品編碼 232804
出版日期 內容資訊 英文 503 Pages
訂單完成後即時交付
價格
特發性肺纖維化:開發中產品分析 Idiopathic Pulmonary Fibrosis - Pipeline Review, H1 2020
出版日期: 2020年04月30日內容資訊: 英文 503 Pages
簡介

特發性肺纖維化(IPF),是肺的孤立性進行性疾病。有乾咳、呼吸急促(特別是運動中/運動後)、持續性的疲勞、體重減少等症狀。治療包含抗氧化劑、生物學的反應調節劑、抗纖維化劑、抗凝劑等。

本報告提供特發性肺纖維化的治療藥開發情形調查分析,提供您開發中產品概要,臨床實驗的各階段產品概要,主要企業簡介,藥物簡介,開發中產品的最新趨勢,最新消息和新聞稿等相關的系統性資訊。

簡介

  • 調查範圍

特發性肺纖維化 - 概要

特發性肺纖維化 - 治療藥的開發

  • 開發平台概要
  • 各企業的開發平台趨勢
  • 各大學·研究機關的開發平台趨勢
  • 企業開發中的產品
  • 大學·研究機關開發中的產品

特發性肺纖維化 - 治療藥的評估

  • 標的別
  • 各作用機制
  • 各給藥途徑
  • 各分子類型

特發性肺纖維化的開發治療藥的企業

  • AdAlta Ltd
  • Aeolus Pharmaceuticals Inc
  • Allinky Biopharma
  • apceth Biopharma GmbH
  • Apellis Pharmaceuticals Inc
  • 旭化成製藥
  • aTyr Pharma Inc
  • Biogen Inc
  • Bioneer Corp
  • BLR Bio LLC
  • Bristol-Myers Squibb Company
  • Celgene Corp
  • Celldex Therapeutics Inc
  • Chiesi Farmaceutici SpA
  • Compugen Ltd
  • Cynata Therapeutics Ltd
  • F. Hoffmann-La Roche Ltd
  • FibroGen Inc
  • FibroStatin SL
  • Galapagos NV
  • GenKyoTex SA
  • GlaxoSmithKline Plc
  • Glenmark Pharmaceuticals Ltd
  • Global Blood Therapeutics Inc
  • GNI Group Ltd
  • Histocell SL
  • iBio Inc
  • Inventiva
  • Isarna Therapeutics GmbH
  • Kadmon Corp LLC
  • Kasiak Research Pvt Ltd
  • Kyorin Pharmaceutical Co Ltd
  • Lung Therapeutics Inc
  • Merck & Co Inc
  • miRagen Therapeutics Inc
  • MorphoSys AG
  • Nuevolution AB
  • Pharmaxis Ltd
  • Promedior Inc
  • ProMetic Life Sciences Inc
  • Pulmatrix Inc
  • Re-Pharm Ltd
  • Redx Pharma Plc
  • Respira Therapeutics Inc
  • Ribomic Inc
  • Saje Pharma LLC
  • Samumed LLC
  • Sanofi
  • Sorrento Therapeutics Inc
  • SPR Biosciences LLC
  • Therabron Therapeutics Inc
  • Unity Biotechnology Inc
  • Vicore Pharma AB
  • Yuhan Corp

藥物簡介

特發性肺纖維化 - 暫停中的計劃

特發性肺纖維化 - 開發中止的產品

特發性肺纖維化 - 產品開發的里程碑

  • 主要消息和新聞稿

附錄

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC12176IDB

Summary:

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Idiopathic Pulmonary Fibrosis - Pipeline Review, H1 2020, provides an overview of the Idiopathic Pulmonary Fibrosis (Respiratory) pipeline landscape.

Idiopathic pulmonary fibrosis (IPF) is a progressive and fatal disease characterized by inflammation and scarring of lung tissue and loss of lung function. Symptoms of IPF include dry cough, shortness of breath, especially during or after physical activity, lasting tiredness and weight loss. Risk factors include smoking, environmental exposure, viral infections, family history and abnormal acid reflux. Treatment includes antioxidants, biological response modulators, anti-fibrotic agents and anticoagulants.

Report Highlights:

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Idiopathic Pulmonary Fibrosis - Pipeline Review, H1 2020, provides comprehensive information on the therapeutics under development for Idiopathic Pulmonary Fibrosis (Respiratory), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Idiopathic Pulmonary Fibrosis (Respiratory) pipeline guide also reviews of key players involved in therapeutic development for Idiopathic Pulmonary Fibrosis and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 1, 3, 14, 30, 4, 95, 18 and 4 respectively. Similarly, the Universities portfolio in Preclinical and Discovery stages comprises 5 and 3 molecules, respectively.

Idiopathic Pulmonary Fibrosis (Respiratory) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope:

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Idiopathic Pulmonary Fibrosis (Respiratory).
  • The pipeline guide reviews pipeline therapeutics for Idiopathic Pulmonary Fibrosis (Respiratory) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Idiopathic Pulmonary Fibrosis (Respiratory) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Idiopathic Pulmonary Fibrosis (Respiratory) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Idiopathic Pulmonary Fibrosis (Respiratory)

Reasons to Buy:

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Idiopathic Pulmonary Fibrosis (Respiratory).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Idiopathic Pulmonary Fibrosis (Respiratory) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table of Contents

Table of Contents

  • Introduction
    • Idiopathic Pulmonary Fibrosis - Overview
    • Idiopathic Pulmonary Fibrosis - Therapeutics Development
    • Idiopathic Pulmonary Fibrosis - Therapeutics Assessment
    • Idiopathic Pulmonary Fibrosis - Companies Involved in Therapeutics Development
    • Idiopathic Pulmonary Fibrosis - Drug Profiles
    • Idiopathic Pulmonary Fibrosis - Dormant Projects
    • Idiopathic Pulmonary Fibrosis - Discontinued Products
    • Idiopathic Pulmonary Fibrosis - Product Development Milestones
    • Appendix

    List of Tables

    • Number of Products under Development for Idiopathic Pulmonary Fibrosis, H1 2020
    • Number of Products under Development by Companies, H1 2020
    • Number of Products under Development by Companies, H1 2020 (Contd..1), H1 2020
    • Number of Products under Development by Companies, H1 2020 (Contd..2), H1 2020
    • Number of Products under Development by Companies, H1 2020 (Contd..3), H1 2020
    • Number of Products under Development by Companies, H1 2020 (Contd..4), H1 2020
    • Number of Products under Development by Companies, H1 2020 (Contd..5), H1 2020
    • Number of Products under Development by Companies, H1 2020 (Contd..6), H1 2020
    • Number of Products under Development by Universities/Institutes, H1 2020
    • Products under Development by Companies, H1 2020
    • Products under Development by Companies, H1 2020 (Contd..1), H1 2020
    • Products under Development by Companies, H1 2020 (Contd..2), H1 2020
    • Products under Development by Companies, H1 2020 (Contd..3), H1 2020
    • Products under Development by Companies, H1 2020 (Contd..4), H1 2020
    • Products under Development by Companies, H1 2020 (Contd..5), H1 2020
    • Products under Development by Companies, H1 2020 (Contd..6), H1 2020
    • Products under Development by Companies, H1 2020 (Contd..7), H1 2020
    • Products under Development by Companies, H1 2020 (Contd..8), H1 2020
    • Products under Development by Companies, H1 2020 (Contd..9), H1 2020
    • Products under Development by Universities/Institutes, H1 2020
    • Number of Products by Stage and Target, H1 2020
    • Number of Products by Stage and Target, H1 2020 (Contd..1), H1 2020
    • Number of Products by Stage and Target, H1 2020 (Contd..2), H1 2020
    • Number of Products by Stage and Target, H1 2020 (Contd..3), H1 2020
    • Number of Products by Stage and Target, H1 2020 (Contd..4), H1 2020
    • Number of Products by Stage and Target, H1 2020 (Contd..5), H1 2020
    • Number of Products by Stage and Mechanism of Action, H1 2020
    • Number of Products by Stage and Mechanism of Action, H1 2020 (Contd..1), H1 2020
    • Number of Products by Stage and Mechanism of Action, H1 2020 (Contd..2), H1 2020
    • Number of Products by Stage and Mechanism of Action, H1 2020 (Contd..3), H1 2020
    • Number of Products by Stage and Mechanism of Action, H1 2020 (Contd..4), H1 2020
    • Number of Products by Stage and Mechanism of Action, H1 2020 (Contd..5), H1 2020
    • Number of Products by Stage and Route of Administration, H1 2020
    • Number of Products by Stage and Molecule Type, H1 2020
    • Idiopathic Pulmonary Fibrosis - Pipeline by Abeome Corp, H1 2020
    • Idiopathic Pulmonary Fibrosis - Pipeline by Accendatech Au Pty Ltd, H1 2020
    • Idiopathic Pulmonary Fibrosis - Pipeline by AdAlta Ltd, H1 2020
    • Idiopathic Pulmonary Fibrosis - Pipeline by Afimmune Biopharma Ltd, H1 2020
    • Idiopathic Pulmonary Fibrosis - Pipeline by Algernon Pharmaceuticals Inc, H1 2020
    • Idiopathic Pulmonary Fibrosis - Pipeline by Altavant Sciences*Inc, H1 2020
    • Idiopathic Pulmonary Fibrosis - Pipeline by Altay Therapeutics Inc, H1 2020
    • Idiopathic Pulmonary Fibrosis - Pipeline by Amgen Inc, H1 2020

    List of Figures

    • Number of Products under Development for Idiopathic Pulmonary Fibrosis, H1 2020
    • Number of Products under Development by Companies, H1 2020
    • Number of Products under Development by Universities/Institutes, H1 2020
    • Number of Products by Top 10 Targets, H1 2020
    • Number of Products by Stage and Top 10 Targets, H1 2020
    • Number of Products by Top 10 Mechanism of Actions, H1 2020
    • Number of Products by Stage and Top 10 Mechanism of Actions, H1 2020
    • Number of Products by Top 10 Routes of Administration, H1 2020
    • Number of Products by Stage and Top 10 Routes of Administration, H1 2020
    • Number of Products by Top 10 Molecule Types, H1 2020
    • Number of Products by Stage and Top 10 Molecule Types, H1 2020